A recent study reported that both tyrosine phosphorylation of signal transducer and activator of transcription 5 (STAT5) and STAT1 in response to IL-2 stimulation were impaired in melanoma patients and this was correlated with increasing clinical stage [28]. The gene discussed is STAT1; the disease is melanoma.